Time-of-day immunotherapy for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether giving immunotherapy at a specific time of day can improve its effectiveness for advanced melanoma that cannot be removed by surgery. It may help you if you have stage IV melanoma and have not had immunotherapy in the last year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV melanoma that cannot be removed by surgery.
- Your melanoma type is cutaneous, acral, or mucosal (not uveal).
- You have not had immunotherapy in the last year.
- Any brain metastases must be smaller than 2 cm, not causing symptoms, and not bleeding.
- You are generally active and able to care for yourself (ECOG 0 or 1).
- You are not taking high doses of steroids (more than 10 mg prednisone daily) and do not have an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether special light therapy timed to your body's natural rhythms can improve how well your immune cells (called TIL therapy) fight advanced melanoma. You must already be enrolled in standard TIL therapy and have progressed despite previous immunotherapy.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This study tests whether giving immunotherapy (medicines that help your immune system fight cancer) at specific times of day—aligned with your body's natural rhythms—works better for advanced melanoma. Researchers will randomly assign you to receive treatment either on a timed schedule or a standard schedule.
This study tests two different ways of giving immunotherapy drugs (anti-CTLA-4 and anti-PD-1 checkpoint inhibitors) to treat advanced melanoma that cannot be surgically removed. Researchers want to see if giving one drug through the skin (intradermal) instead of through the vein works as well or better.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Hear when a new Clinical Stage IV Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.